Investigational drug · Phase 2
amsulostat
Also called: PXS-5505
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "amsulostat"
First trial start
2021
Feb 18, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "amsulostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelofibrosis
- Primary Myelofibrosis (PMF)
- Post- Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis
Approved drugs for the same conditions: Myelofibrosis · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "amsulostat" as an intervention, largest first.
SyntaraIndustry
NCT04676529 · 43 participants · Start Feb 18, 2021 · Primary completion Jul 9, 2025
Drug: PXS-5505 · For: Myelofibrosis; Primary Myelofibrosis (PMF); Post- Essential Thrombocythemia Myelofibrosis and 1 more
Sites: Birmingham, Alabama; Winston-Salem, North Carolina; Houston, Texas · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma.
Flaherty RL, Hughes F, Sflomos G, et al. · Cancer Res 2026
- Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer.
Laforêts F, Kotantaki P, Elorbany S, et al. · iScience 2026
- A phase I/IIa trial of PXS-5505, a novel pan-lysyl oxidase inhibitor, in advanced myelofibrosis.
Vachhani P, Tan P, Watson AM, et al. · Haematologica 2025
- Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.
Burchard PR, Ruffolo LI, Ullman NA, et al. · Hepatol Commun 2024
- A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
Chitty JL, Yam M, Perryman L, et al. · Nat Cancer 2023
- Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies.
Xu Q, Streuer A, Jann JC, et al. · Nat Commun 2023
Also in development for Myelofibrosis
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- RovadicitinibTQ05105Phase 35 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- PelabresibDAK539, CPI-0610Phase 34 trials
Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
- GB2064Phase 21 trial
Galecto Biotech AB · Myelofibrosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.